C5 and paroxysmal nocturnal hemoglobinuria: Complement inhibitors are currently approved by the Food and Drug Administration for the treatment of paroxysmal nocturnal hemoglobinuria, blocking terminal complement activation by binding to C5 so that the process of producing pro-inflammatory C5a molecules and MAC scleral complex formation is stopped.